Ozempic Gastroparesis Settlement: Key Factors in Claim Valuation

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Registries to Targeted Risk Assessment

The legacy of mass production in health information has long centered on broad, accessible science communication. Platforms such as hemophiliaregistry.com exemplify this heritage, offering general disease registries and educational resources aimed at public awareness. This foundational approach prioritized widespread dissemination of knowledge without delving into specific product exposures or occupational risks. Over time, however, the landscape of health information has evolved to address more targeted concerns arising from therapeutic interventions. As pharmaceutical manufacturing scaled, so did the need to monitor real-world outcomes beyond clinical trials. This shift naturally extends to evaluating adverse event patterns associated with widely prescribed medications. In the context of mass production, the focus now moves from general health literacy to the systematic assessment of exposure-related risks. Specifically, the widespread use of glucagon-like peptide-1 receptor agonists has prompted scrutiny of gastrointestinal safety profiles. This transition acknowledges that large-scale drug distribution necessitates careful monitoring of potential complications, including those affecting gastric motility.

Ozempic and Gastroparesis: A Bridge from General Safety to Specific Harm

The following discussion examines the valuation factors relevant to claims involving such exposures, maintaining the same commitment to clear, evidence-informed communication that defined earlier public health registries. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its pharmacological action slows gastric emptying, a mechanism that can lead to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, resulting in symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and abdominal discomfort. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. In the context of Ozempic use, the onset of gastroparesis may be insidious, often emerging during dose escalation or after prolonged treatment.

Evidence Linking Ozempic to Gastroparesis: Pharmacological and Surveillance Data

The FDA Adverse Event Reporting System (FAERS) database lists "impaired gastric emptying" as a frequently reported adverse event associated with Ozempic, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This signal is consistent with the drug's known effect on gastric motility. The mechanistic pathway linking Ozempic to gastroparesis involves the activation of GLP-1 receptors in the gastrointestinal tract, which inhibits antral contractions and slows gastric emptying. While this effect is intended to promote satiety and reduce postprandial glucose excursions, it can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The risk is heightened during dose escalation, as evidenced by clinical trial data showing that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also higher in the Ozempic groups (0.5 mg: 3.1%; 1 mg: 3.8%) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with higher doses (1 mg and 2 mg), gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) than with 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Adequacy of Warnings and Settlement Considerations

Adequacy of warnings regarding Ozempic and gastroparesis is a critical factor in settlement considerations. The prescribing label for Ozempic includes gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, dyspepsia, and gastroesophageal reflux disease, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label notes that the majority of nausea, vomiting, and/or diarrhea occurred during dose escalation, and that these events led to discontinuation in a small percentage of patients. However, the term "impaired gastric emptying" is not included in the label's adverse reactions section, despite its prominence in FAERS reports. This discrepancy may form the basis for claims that the manufacturer failed to adequately warn patients and healthcare providers about the risk of gastroparesis. Settlement-related considerations for affected patients hinge on several factors. First, the strength of the causal link between Ozempic and gastroparesis is supported by both pharmacological plausibility and post-marketing surveillance data. Second, the timeline between exposure and documented harm is relevant: patients who developed gastroparesis shortly after initiating Ozempic or during dose escalation may have a stronger claim than those with pre-existing gastrointestinal conditions. Third, the severity and duration of gastroparesis symptoms, including hospitalizations, need for nutritional support, and impact on quality of life, will influence claim valuation. Fourth, the adequacy of medical records documenting the diagnosis and its temporal relationship to Ozempic use is essential. Finally, the presence of other risk factors for gastroparesis, such as diabetes itself (which is also a risk factor for gastroparesis), may complicate causation analysis.

Summary of Evidence and Claim Valuation Factors

In summary, the evidence from clinical trials and FAERS reports indicates a significant association between Ozempic use and gastrointestinal adverse events, including impaired gastric emptying. The absence of explicit gastroparesis warnings in the label may support claims of inadequate risk communication. Settlement valuations will depend on individual patient factors, including the timing of symptom onset, severity of harm, and documentation of the causal link. Patients pursuing claims should consult with legal and medical experts to assess the strength of their case. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to gastroparesis in susceptible individuals. The FDA Adverse Event Reporting System has received over 2,600 reports of impaired gastric emptying associated with Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Clinical trials also show higher rates of gastrointestinal adverse events with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What factors affect the valuation of an Ozempic gastroparesis claim?

Key factors include the strength of the causal link, timing of symptom onset relative to Ozempic use, severity and duration of symptoms, adequacy of medical records, and presence of other risk factors like diabetes. The absence of explicit gastroparesis warnings in the label may also support claims of inadequate risk communication.

Does the Ozempic label warn about gastroparesis?

The prescribing label lists gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but does not explicitly mention gastroparesis or impaired gastric emptying (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This discrepancy may be relevant for claims regarding failure to warn.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.